<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg"/></p>
<p>凭借优化的 CAR 序列知识产权和细胞选择性 LNP 技术，Liberate Bio 能够推进体内 CAR-M 疗法。图片来源：sirtravelalot / Shutterstock.com。</p>
<p>Liberate Bio 已获得与针对髓系细胞（如单核细胞和巨噬细胞）量身定制的嵌合抗原受体（CAR）设计相关的独占和非独占专利许可。</p>
<p>这些许可来自 Carisma Therapeutics 和宾夕法尼亚大学，包含专门为这些免疫细胞群体的功能而设计的方法和构建体。</p>
<h3>深入了解 GlobalData</h3>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多发性骨髓瘤中的应用（Ka...</h4>
<ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<p>报告</p>
<h4>LOA 和 PTSR 模型 - Lisocabtagene Maraleucel 在慢性淋巴细胞白血病中的应用</h4>
<h5>深入了解 GlobalData</h5>
<p>商业智能的黄金标准。</p>
<p>了解更多</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>发现高效的 B2B 营销</h4>
<p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
<p>了解更多</p>
<p>这些设计补充了 Liberate Bio 的脂质纳米颗粒（LNP）递送平台，使其能够在体内选择性地编程巨噬细胞和单核细胞。</p>
<p>凭借优化的 CAR 序列知识产权和细胞选择性 LNP 技术，Liberate Bio 现在有能力将体内 CAR-M 疗法推进到临床评估阶段。</p>
<p>Liberate Bio 的 Raptor 平台在非人类灵长类动物中直接筛选 LNP，以发现针对肝外免疫细胞的递送载体。</p>
<p>该公司之前披露，其领先的 LNP 通过选择性编程单核细胞和巨噬细胞，导致非人类灵长类动物中循环 B 细胞的去除率超过 99%。</p>
<p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData 战略情报</p>
<h1>美国关税正在变化 - 你会反应还是预见？</h1>
<p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
<p>由 GlobalData 提供</p>
<p>了解更多关于战略情报</p>
<p>Liberate Bio 的首席科学官 Walter Strapps 表示：“这项许可协议显著增强了我们的临床项目。髓系细胞具有与 T 细胞不同的独特生物学，优化其激活和持久性的 CAR 构建体至关重要。</p>
<p>“通过将经过验证的 CAR 设计方法与我们的髓系选择性 LNP 平台相结合，我们正在建立一种差异化且高度集成的体内细胞疗法方法。”</p>
<p>Liberate Bio 首席执行官 Shawn Davis 表示：“体内 CAR-M 代表了免疫重编程的新篇章。通过将最佳递送与优化的髓系 CAR 设计结合在一起，我们正在建立一个持久的基础，以便为 CAR-T 提供可扩展且潜在更安全的替代方案——能够覆盖更广泛的自身免疫和肿瘤指征患者群体。”</p>
<p>该公司计划将其初始的体内 CAR-M 候选药物推进到临床试验（IND）启用研究，目标是在 2026 年下半年通过研究者发起的试验进行初步临床评估。</p>

生物科技 ETF - VanEck Vectors

IBBQ

标普生物技术 ETF - SPDR

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

医药突破 ETF - ALPS

2 倍做多纳斯达克生物技术 ETF - ProShares

CARM

动态生物技术与基因组 ETF - Invesco

<p>Liberate Bio 已获得针对特定于髓系细胞的 CAR 设计专利的独占和非独占许可，增强其体内 CAR-M 疗法。这些许可来自 Carisma Therapeutics 和宾夕法尼亚大学，包括针对单核细胞和巨噬细胞的工程化方法。该公司计划在 2026 年底之前将其 CAR-M 候选药物推进至临床试验，利用其脂质纳米颗粒技术进行靶向免疫细胞编程</p>

<p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/uploads/sites/24/2026/03/PT-06-03-2026-shutterstock_524659801-430x241.jpg"/></p>
<p>With optimised CAR-sequence intellectual property and cell-selective LNP technology, Liberate Bio can advance in vivo CAR-M therapies. Credit: sirtravelalot / Shutterstock.com.</p>
<div class="lb-trans"><p>凭借优化的 CAR 序列知识产权和细胞选择性 LNP 技术，Liberate Bio 能够推进体内 CAR-M 疗法。图片来源：sirtravelalot / Shutterstock.com。</p>
</div><p>Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages.</p>
<div class="lb-trans"><p>Liberate Bio 已获得与针对髓系细胞（如单核细胞和巨噬细胞）量身定制的嵌合抗原受体（CAR）设计相关的独占和非独占专利许可。</p>
</div><p>The licences sourced from Carisma Therapeutics and the University of Pennsylvania include methods and constructs specifically engineered for function within these immune cell populations.</p>
<div class="lb-trans"><p>这些许可来自 Carisma Therapeutics 和宾夕法尼亚大学，包含专门为这些免疫细胞群体的功能而设计的方法和构建体。</p>
</div><h3>Go deeper with GlobalData</h3>
<div class="lb-trans"><h3>深入了解 GlobalData</h3>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Idecabtagene Vicleucel in Multiple Myeloma (Ka...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Idecabtagene Vicleucel 在多发性骨髓瘤中的应用（Ka...</h4>
</div><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
<div class="lb-trans"><ul>
<li><img src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png" alt="ReportsLogo" original-src="/wp-content/themes/goodlife-wp-B2B/assets/img/report.png"/></li>
</ul>
</div><p>Reports</p>
<div class="lb-trans"><p>报告</p>
</div><h4>LOA and PTSR Model - Lisocabtagene Maraleucel in Chronic Lymphocyti...</h4>
<div class="lb-trans"><h4>LOA 和 PTSR 模型 - Lisocabtagene Maraleucel 在慢性淋巴细胞白血病中的应用</h4>
</div><h5>Go deeper with GlobalData</h5>
<div class="lb-trans"><h5>深入了解 GlobalData</h5>
</div><p>The gold standard of business intelligence.</p>
<div class="lb-trans"><p>商业智能的黄金标准。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg" alt="" original-src="https://www.pharmaceutical-technology.com/wp-content/themes/goodlife-wp-B2B/assets/images/GMS-logo.svg"/></p>
<h4>Discover B2B Marketing That Performs</h4>
<div class="lb-trans"><h4>发现高效的 B2B 营销</h4>
</div><p>Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.</p>
<div class="lb-trans"><p>结合商业智能和编辑卓越，覆盖 36 个领先媒体平台的专业人士。</p>
</div><p>Find out more</p>
<div class="lb-trans"><p>了解更多</p>
</div><p>The designs complement Liberate Bio’s lipid nanoparticle (LNP) delivery platform, which enables the selective programming of macrophages and monocytes in vivo.</p>
<div class="lb-trans"><p>这些设计补充了 Liberate Bio 的脂质纳米颗粒（LNP）递送平台，使其能够在体内选择性地编程巨噬细胞和单核细胞。</p>
</div><p>With both the optimised CAR-sequence intellectual property and its cell-selective LNP technology, Liberate Bio is now positioned to advance in vivo CAR-M therapies into clinical assessment.</p>
<div class="lb-trans"><p>凭借优化的 CAR 序列知识产权和细胞选择性 LNP 技术，Liberate Bio 现在有能力将体内 CAR-M 疗法推进到临床评估阶段。</p>
</div><p>Liberate Bio’s Raptor platform conducts direct screening of LNPs in non-human primates to discover delivery vehicles aimed at extrahepatic immune cells.</p>
<div class="lb-trans"><p>Liberate Bio 的 Raptor 平台在非人类灵长类动物中直接筛选 LNP，以发现针对肝外免疫细胞的递送载体。</p>
</div><p>The company has previously disclosed that its lead LNP resulted in more than 99% depletion of circulating B cells in non-human primates by selectively programming monocytes and macrophages.</p>
<div class="lb-trans"><p>该公司之前披露，其领先的 LNP 通过选择性编程单核细胞和巨噬细胞，导致非人类灵长类动物中循环 B 细胞的去除率超过 99%。</p>
</div><p><img src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png" alt="" original-src="/wp-content/themes/goodlife-wp-B2B/assets/images/strategic-int.png"/></p>
<p>GlobalData Strategic Intelligence</p>
<div class="lb-trans"><p>GlobalData 战略情报</p>
</div><h1>US Tariffs are shifting - will you react or anticipate?</h1>
<div class="lb-trans"><h1>美国关税正在变化 - 你会反应还是预见？</h1>
</div><p>Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.</p>
<div class="lb-trans"><p>不要让政策变化让你措手不及。通过实时数据和专家分析保持主动。</p>
</div><p>By GlobalData</p>
<div class="lb-trans"><p>由 GlobalData 提供</p>
</div><p>Learn more about Strategic Intelligence</p>
<div class="lb-trans"><p>了解更多关于战略情报</p>
</div><p>Liberate Bio’s chief scientific officer Walter Strapps said: “This licensing agreement meaningfully strengthens our clinical programmes. Myeloid cells have unique biology distinct from T cells, and CAR constructs optimised for their activation and persistence are essential.</p>
<div class="lb-trans"><p>Liberate Bio 的首席科学官 Walter Strapps 表示：“这项许可协议显著增强了我们的临床项目。髓系细胞具有与 T 细胞不同的独特生物学，优化其激活和持久性的 CAR 构建体至关重要。</p>
</div><p>“By combining validated methods for CAR designs with our myeloid-selective LNP platform, we are building a differentiated and highly integrated approach to in vivo cell therapy.”</p>
<div class="lb-trans"><p>“通过将经过验证的 CAR 设计方法与我们的髓系选择性 LNP 平台相结合，我们正在建立一种差异化且高度集成的体内细胞疗法方法。”</p>
</div><p>Liberate Bio CEO Shawn Davis said: “In vivo CAR-M represents a new chapter in immune reprogramming. By uniting best-in-class delivery with optimised myeloid CAR designs, we are establishing a durable foundation for a scalable and potentially safer alternative to CAR-T — one capable of reaching broader patient populations across autoimmune and oncology indications.”</p>
<div class="lb-trans"><p>Liberate Bio 首席执行官 Shawn Davis 表示：“体内 CAR-M 代表了免疫重编程的新篇章。通过将最佳递送与优化的髓系 CAR 设计结合在一起，我们正在建立一个持久的基础，以便为 CAR-T 提供可扩展且潜在更安全的替代方案——能够覆盖更广泛的自身免疫和肿瘤指征患者群体。”</p>
</div><p>The company intends to progress its initial in vivo CAR-M candidate into investigational new drug (IND)-enabling studies, targeting initial clinical evaluation via an investigator-initiated trial in the latter half of 2026.</p>
<div class="lb-trans"><p>该公司计划将其初始的体内 CAR-M 候选药物推进到临床试验（IND）启用研究，目标是在 2026 年下半年通过研究者发起的试验进行初步临床评估。</p>
</div>

Liberate Bio 获得了髓系特异性 CAR 设计专利的许可